Showing 117 of 117on this page. Filters & sort apply to loaded results; URL updates for sharing.117 of 117 on this page
cormedix Logo 4-2020 - CorMedix | Prevention of cardiac, renal and ...
CorMedix Announces Enrollment and Dosing of First Patient in Phase 3 ...
CorMedix (CRMD) - P/B ratio
CorMedix to Participate in Upcoming Investor Conferences
Will 2021 Hold Significant Growth For CorMedix (CRMD)?
Melinta Therapeutics Announces Strategic Acquisition by CorMedix ...
Careers - CorMedix | Prevention of cardiac, renal and infectious diseases
CorMedix - 2026 Company Profile, Team, Funding & Financials - Tracxn
Cormedix logo in transparent PNG format
CorMedix Stock Breaks Out To 2-Month High: Analysts Reset Price Targets ...
Why CorMedix Could be the Biopharma Name to Watch Early in 2026
CorMedix $CRMD Stock Review - YouTube
CorMedix Acquires Melinta for $300M, Adds 7 Commercial Products | CRMD ...
CorMedix Therapeutics Price Target and Financial P... | FMP
CORMEDIX DefenCath TM : A potentially new standard - of - care in the ...
Cormedix SWOT Analysis & Strategic Plan 2025-Q4
Sponsor Spotlight: CORMEDIX! Our Gold Level Sponsor, CorMedix Inc., is ...
CORMEDIX - Cormedix Inc. Trademark Registration
CorMedix logo in transparent PNG and vectorized SVG formats
CorMedix signs agreement to acquire Melinta for $300m
CorMedix Announces $85M Stock Offering Amid Strategic Expansion Plans
CorMedix Acquires Melinta Therapeutics for $300 Million to Expand Anti ...
FDA Approves CorMedix Inc’s Treatment for Bloodstream Infections in ...
CorMedix Inc. Stock Overview — CRMD Summary & Analysis — Roic AI
Cormedix Inc (CRMD) Q1 2025: Everything You Need To Know Ahead Of Earnings
CorMedix Wins FDA Approval for Antimicrobial Drug Combo After Two ...
Home - CorMedix
CorMedix Emerges as Top Biopharma Name to Watch in Early 2026 with ...
CorMedix to Buy Melinta Therapeutics for $300 Million - WSJ
Inside the Q: CorMedix Hits Profitability as DefenCath Sales Gain ...
Cormedix Inc. sets 2025 revenue guidance of $325–$350M | BioTech Health ...
CorMedix raises 2025 revenue guidance to $390M-$410M amid accelerated ...
Home - CorMedix | Prevention of cardiac, renal and infectious diseases
CorMedix Soars 32% on Upbeat Q4 Forecast - Wall Street Pit
CORMEDIX INC. ANNOUNCES COMMERCIAL AGREEMENT WITH ARC DIALYSIS, LLC ...
CORMEDIX INC. REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND ...
CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug
CorMedix Inc (CRMD) News, Articles, Events & Latest Updates
CorMedix Receives CE Mark for Neutrolin® Catheter Lock Solution
AAKP Innovator Series | CorMedix – AAKP
CRMD | CorMedix Inc. Announces FDA Acceptance of Resubmission of New ...
CorMedix (CRMD) Revenue to Hit $350M After Melinta Buyout • BioTech ...
Cormedix refuerza los cuidados agudos con la adquisición de Melinta ...
CorMedix Stock Hits New 52-Week High On Updated Guidance: The Details ...
LOCK-IT-100 - CorMedix | Prevention of cardiac, renal and infectious ...
CorMedix Inc. (CRMD) Plunges 1.90% to 2025 Low
CorMedix Inc. (CRMD) Latest Press Releases & Corporate News - Yahoo Finance
CRMD Soars 19.40% as CorMedix Announces Preliminary Q1 Results and ...
CorMedix Inc. Reports First Quarter 2021 Financial Results and Provides ...
FDA Accepts Resubmission of DefenCath New Drug Application by CorMedix Inc
CORMEDIX INC. REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES ...
CorMedix is expanding our team as we build commercial infrastructure ...
CorMedix Completes Phase III Enrollment for REZZAYO BMT Study | CRMD ...
CORMEDIX INC. REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES ...
CorMedix Inc. Prepares for Q3 2025 Financial Results Release ...
CorMedix Announces Q3 Earnings That Includes First Full Quarter of ...
CorMedix (CRMD) Surges 19.5%: Is This an Indication of Further Gains?
CorMedix : Receives Fast Track Designation for Neutrolin® - MarketScreener
CorMedix 2.0: New Leadership, New Approval, New Focus (NASDAQ:CRMD ...
CorMedix buys out Melinta for $300M, adding 7 marketed products
Cormedix
CorMedix Inc. (CRMD) Acquires Melinta Therapeutics to Expand Hospital ...
CorMedix Inc (NASDAQ:CRMD) Fits a Proven Growth Strategy with Strong ...
CorMedix Shares Drop 1.28% as $380M Volume Ranks 291st in Market ...
CorMedix Raises 2025 Net Revenue Guidance to at least $375M | CRMD ...
Needham Maintains a Buy Rating on CorMedix (CRMD) With a $20 PT
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release
Cormedix (CRMD) - P/E ratio
CORMEDIX INC. REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES ...
CorMedix (CRMD): A Hidden Growth Gem with 60% Upside Potential
Cormedix Completes Enrollment for Phase III Rezzayo Trial
#asembiaaxs24 | CorMedix Therapeutics
Logo de Cormedix au format PNG transparent
CorMedix Sets Q4 and Full Year 2024 Earnings Call for March 25 | CRMD ...
CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the ...
CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE of RESUBMISSION of NEW DRUG ...
CorMedix Inc. - Needham
Cormedix Stock Price Forecast. Should You Buy CRMD?
CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL ...
CORMEDIX INC. REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES ...
Sepsis Alliance Institute: CorMedix Sponsored Session: Reducing Risk of ...
CRMD | CorMedix Inc. Announces U.S. Inpatient Commercial Availability ...
코메딕스(CRMD) 4,000만 달러 퍼블릭 오퍼링(회사소개) CorMedix Inc. : 네이버 블로그
Home - Rezzayo
CorMedixTO ACQUIRE MELINTA THERAPEUTICS, CREATING DIVERSIFIED
Logos of pharmaceutical companies
DEFENCATH (CorMedix Inc.): FDA Package Insert
EX-99.2 3 ea156242ex99-2_cormedix.htm CORPORATE PRESENTATION DATED ...
CorMedix, Inc. - PRISM MarketView
CorMedix: Infected With Hype, Valuation Swollen – Night Market Research
FDA signs off on CorMedix's drug which reduces risk of infection
CorMedix, Inc. - AnnualReports.co.uk
How This Tiny Biotech Could Save Millions of Lives—and Billions in ...
FDA Label for Defencath Solution Intraluminal - Indications, Usage ...
CorMedix:Exceeding Expectations (NASDAQ:CRMD) | Seeking Alpha
US FDA approves CorMedix's drug for bloodstream infections | Reuters
CorMedix: Finally In Commercialization Mode (NASDAQ:CRMD) | Seeking Alpha
Sepsis Alliance Institute: Sepsis Alliance AMR Conference 2025: Homepage
Defencath: Package Insert / Prescribing Information / MOA
Exhibitors
